Optibrium, a leading developer of software and AI solutions for molecular design, has announced it has secured a strategic financing package with Shawbrook, a specialist UK bank that provides finance to established UK businesses on high growth trajectories. This multi-million-pound deal will enable Optibrium to continue to build its offering to global pharmaceutical and biotech teams, further increasing the speed and efficiency of their drug discovery timelines...

Optibrium, a leading developer of software and AI solutions for drug discovery, has announced the release of StarDrop 7.6, the latest version of its platform for small molecule design, optimisation and analysis. As part of the release, Optibrium introduces a new extension, Idea Tracker, with which medicinal chemists can now easily trace molecular design and optimisation decisions through every step of the complex discovery process, from idea conception to selecting candidates for synthesis...

Optibrium, a leading developer of software and AI solutions for drug discovery, has announced that its drug discovery platform, StarDrop, is now also available in the cloud environment. Backed by Optibrium’s ISO 27001-accredited information security system, this cloud-first approach offers StarDrop users several benefits in terms of flexible access and ease of product deployment, maintenance and data security...

Optibrium, a leading developer of software and AI solutions for drug discovery, has announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology, BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division...

Optibrium, a leading developer of software and AI for small molecule discovery, and PostEra, an AI-first biotechnology company with advanced machine learning (ML) technology for preclinical discovery, has announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software. StarDrop’s comprehensive suite of drug discovery software enables de novo compound design, optimisation, and data analysis and now, with the seamless integration...

Optibrium™, a developer of software for drug discovery, today announced the release of the newest version of StarDrop™, a comprehensive software platform for small molecule design, optimisation and data analysis. The new release, StarDrop 7.0, further extends the software’s compound design strategies, provides enhanced workflows, and seamlessly connects with Optibrium’s Cerella™ platform, delivering unique Artificial Intelligence (AI) capabilities to drug discovery scientists....

Optibrium™, a developer of software for drug discovery, has announced a collaboration with MSD tradename of Merck & Co., Inc, Kenilworth NJ USA. As part of the collaboration MSD has adopted Optibrium’s StarDrop™ software as a central component of their cheminformatics infrastructure. The collaboration, between MSD and Optibrium will include integration of StarDrop with MSD’s in-house capabilities and the joint development of new tools, to improve cycle times...

This year, in addition to the academic year course ‘Honors Computational Medicinal Chemistry’, 80 rising juniors and seniors will embark upon a special summer short-course entitled ‘Computing COVID-19’, utilizing StarDrop in conjunction with other bioinformatics tools. Optibrium’s lead product, StarDrop, is a comprehensive suite of integrated software...

Optibrium™, BioSolveIT™ and Enamine™, leading providers of software and services for drug discovery, announce a three-way collaboration enabling efficient search of Enamine’s REAL Space directly from within Optibrium’s StarDrop™ software. This extension to StarDrop is powered by BioSolveIT’s proprietary Feature Trees (FTrees) technology, to search a gigantic chemical space of over 11 billion readily accessible compounds and identify novel compounds that are similar to a query structure of interest....

Optibrium™, a developer of software for drug discovery, has announced the introduction of StarDrop™ 6.6, the latest version of this comprehensive software platform for small molecule design, optimisation and data analysis. The enhanced software will introduce new in silico modelling approaches, ensuring scientists can easily link two- and three-dimensional structural information, identify potential liabilities and design new compounds with the highest chance of success....

Optibrium™, a developer of software for drug discovery, has announced the introduction of its Augmented Chemistry™ services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects. In discovery projects, it is important to base decisions on reliable data to avoid wasted effort pursuing incorrectly selected compounds...

Optibrium™, a developer of software for drug discovery, has announced the introduction of its Augmented Chemistry™ services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects. In discovery projects, it is important to base decisions on reliable data to avoid wasted effort pursuing incorrectly selected compounds....

The collaboration provides StarDrop™ users with easy access to ICSYNTHlight, an entry-level version of InfoChem’s computer-aided synthesis design (CASD) software to generate synthesis pathways for a target molecule. By stimulating new and unbiased ideas, researchers can explore alternative or novel synthetic routes with the potential to save time and reduce costs...

Optibrium™, a developer of software for drug discovery, has announced it had entered into a collaboration with the University of Nottingham, a pioneering research institution and university. Optibrium’s StarDrop™ software will be available to a number of 4th year MSci Chemistry project students at the University of Nottingham as part of their training in modern drug discovery to aid in the design of potential new candidate compounds for integrin inhibition in fibrotic diseases and malaria, as part of their collaboration with GSK....

Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward as Optibrium™, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project. The program will see Optibrium, which creates software to improve the efficiency and productivity of drug discovery, and Intellegens, a spin out from the University of Cambridge which is focused on a specific form of AI called ‘deep learning’, work with Medicines Discovery Catapult over the next two years...

Optibrium™, a developer of software for drug discovery, has announced it had signed a collaboration agreement with Intellegens, a company developing novel artificial intelligence (AI) software. The collaboration will provide Optibrium clients with access to advanced, proprietary deep learning methods that will extend and improve predictive models to guide the more efficient design and selection of high quality drug candidates.

Novel features include modelling for drug metabolism prediction and virtual library enumeration. Enhanced data visualisation environment for more efficient data analysis and project management. Optibrium™, a developer of software for drug discovery, today announced the launch of version 6.5 of StarDrop™ that provides a complete platform for small molecule design...

Optibrium, a developer of software for small molecule drug discovery, today announced it has appointed Dr. Scott Lyon as Director of Business Development and relocated its Headquarters and R&D facilities, to Cambridge Innovation Park, Cambridge, UK. Optibrium’s move to larger premises is driven by the company’s rapid recent growth and will accommodate future expansion plans as it accelerates its R&D pipeline and extends research into new technologies....

Antimicrobial resistance Biopharma selects StarDrop to guide discovery of next generation of antibiotics

Optibrium™, a developer of software for small molecule discovery, and Bugworks Research Inc. (Bugworks), a company focused on discovering biopharmaceuticals for the treatment of critical and serious bacterial infections, today announced the signing of a two-year agreement to license Optibrium’s StarDrop™ software....

Adds seamless link to compound structure assessment in 3D docking and alignment models

Optibrium, a developer of software for small molecule drug discovery, today announced the launch of version 6.4 of the StarDrop™ platform. The latest release includes a universal Pose Generation Interface, which seamlessly links expertly prepared docking and alignment models with StarDrop’s comprehensive environment for small molecule design, optimisation and data analysis....

Provides MSc students with industry-relevant learning tools and pharma with a new pipeline of candidate compounds

Optibrium™, a developer of software for small molecule design and optimisation today announced it had entered into a collaboration with Imperial College London, the world leading science-based research institution and university, and Drugs for Neglected Diseases initiative (DNDi), a non-profit drug R&D organisation developing new treatments for neglected diseases....

Goldfinch Bio’s researchers select StarDrop to guide successful drug discovery

Optibrium, a developer of software for small molecule discovery, and Goldfinch Bio, a company focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that the company has signed a multi-year agreement to license Optibrium’s StarDrop software....

Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling

Optibrium™ and Lhasa Limited (Lhasa), developers of software for small molecule property prediction, design and optimisation, announced today they have formed a collaborative partnership to research next generation drug metabolism modelling....

New partnership gives researchers improved access to Optibrium’s StarDrop with dedicated local support

Optibrium™, a developer of software for small molecule design and optimisation, announced today that it has appointed Zastra Innovations (Zastra) to be its sole distributor in India for StarDrop™, the company’s flagship product. Zastra will provide researchers in India with the full suite of StarDrop software, combined with local access to expert technical and customer support....

Combines eMolecules’ collection of commercially available chemicals with StarDrop’s data analysis and compound design capabilities in drug discovery

Optibrium™, a developer of software for small molecule design and optimisation today announced a collaboration with eMolecules, the provider of a comprehensive chemical sourcing database. The collaboration provides StarDrop™ users with seamless access to eMolecules’ extensive collection of screening compounds and chemical building blocks, further extending StarDrop’s capabilities to guide compound selection and design...

Partnership combines MolPort’s 6.3 Million HTS Compounds with StarDrop’s data analysis and compound design capabilities

Optibrium™, a developer of software for small molecule design and optimisation, today announced a collaboration with MolPort, the provider of a comprehensive chemicals database, marketplace and order fulfilment platform. The collaboration offers StarDrop™ users fully integrated access to MolPort’s drug discovery database of 6.3 million commercially available screening compounds....

Optibrium™ and Collaborative Drug Discovery (CDD), developers of software products and services for drug discovery and development, today announced a collaboration to integrate the StarDrop™ and CDD Vault® platforms.

This creates a seamless connection in real time between project data, securely held and managed in CDD Vault, and StarDrop’s unique compound design and optimisation capabilities.  Instant access to the latest assay and compound data, with which a project team can share, interpret and model their chemistry, will lead to better decisions and shorter project timelines. CDD Vault is a hosted biological and chemical database that securely manages project data...

Providing instant access to compound data to interpret, model and guide drug discovery decisions

Optibrium™, a developer of software for small molecule drug discovery and optimisation, today announced the commercial launch of a database Query Interface for users of the company’s StarDrop software. The new tool provides an adaptable interface between an organisation’s own research data management systems and StarDrop’s unique compound design and optimisation capabilities. Instant access to the latest data, with which a project team can...

Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery

Optibrium™ and The Edge Software Consultancy, developers of software products and services for drug discovery and development, today announced a collaboration to provide an integrated solution linking the StarDrop™ and BioRails™ platforms....

Optibrium, a developer of software for small molecule discovery, has announced that Janssen Research and Development has signed an agreement to license Optibrium’s StarDrop software.

The agreement will provide a global licence for StarDrop and eight of StarDrop’s optional plug-in modules.

Optibrium™, a developer of software for small molecule drug discovery and optimisation, today announced it will make its StarDrop^TM technology available to an international consortium of academic and not-for profit organisations.

Under the agreement, licensed access to StarDrop software will be provided to support drug discovery projects as part of a global health programme focused on developing new treatments for neglected diseases. Consortium partners are involved in projects to facilitate and speed up the development of therapies for the treatment of so-called “neglected” diseases such as leishmaniasis, sleeping sickness, Chagas disease...

Partnership will deliver a link between 2D and 3D design on medicinal chemists’ desktops

Optibrium™, providers of software for compound optimisation, and chemoinformatics specialist BioSolveIT, today announced that they will collaborate to create seamlessly integrated data analysis, visualisation and simulation software for drug research. The two companies are known for their best-in-class prediction tools for selection and optimisation of potential therapeutics, where it is essential to recognise and resolve potential problems...

Optibrium™ and Certara®, developers of software products and services for drug discovery and development, today announced a collaboration to provide their mutual customers with an integrated solution linking Optibrium’s StarDrop™ with Certara’s D360™ platform. 

The combination of these two products enables researchers to combine the industry-leading self-service data access and analysis capabilities of D360, with StarDrop’s unique, interactive environment that guides compound selection and design decisions in drug discovery, helping project teams to identify high quality compounds more efficiently. D360 provides scientific data integration, access, analysis, and visualisation capabilities for...

Interface between StarDrop and Plexus facilitates seamless access to both software platforms

Optibrium™ and ChemAxon™, developers of software and cheminformatics solutions for drug discovery, today announced the results of a collaboration to integrate ChemAxon’s Plexus™ with Optibrium’s StarDrop™ software suite. The integration of these platforms further enables researchers to develop strategies for efficient, high quality compound library design. The StarDrop software platform from Optibrium facilitates multi-parameter optimisation...

Automatic application of Matsy method for matched series analysis within StarDrop™ will guide compound optimisation in drug discovery

Optibrium™ and NextMove Software, developers of software and chemoinformatics solutions for drug discovery, today announced an agreement to collaborate on the integration of NextMove Software’s Matsy technology with Optibrium’s StarDrop software suite.  The combination of these technologies will help guide scientists to quickly identify novel compounds based on matched molecular series analysis with a high chance of success...

StarDrop 6.0 gives researchers the freedom to explore and organise complex project data in a flexible and intuitive way

Optibrium™, a developer of software for drug discovery, today announced the release of version 6.0 of its StarDrop™ software platform. This major new release introduces Card View™, an intuitive and highly flexible environment to view and interact with compound data in the context of discovery projects.  Card View provides a unique and highly visual way to interpret data on compounds and their relationships, clearly highlighting the best chemistries and...

New Derek™ module for StarDrop™ facilitates the efficient design and selection of safe, efficacious compounds in early drug discovery

Optibrium extends StarDrop’s capabilities to guide the design of high quality compound libraries for drug discovery